bioRxiv Science⌕ Search

Biology subjects

Jang, E. Y.

Publications and source records attributed to Jang, E. Y..

3 recordsLinked to original sources

Age-dependent pathogenicity of two severe fever with thrombocytopenia syndrome viruses in a ferret model

SFTSV is an emerging tick-borne pathogen associated with high case fatality rates, particularly in elderly patients. While severe pathogenicity has been reported in aged ferrets, lethal or clinically significant infection in younger animals and genotype-dependent differences in pathogenicity remain insufficiently defined. In this study, we established a ferret infection model using two Korean clinical isolates representing genotypes B and F and systematically compared disease progression between one-year-old and three-year-old ferrets. Three-year-old ferrets exhibited rapid fever onset, marked body weight loss, early clinical deterioration, severe thrombocytopenia and leukopenia, significant elevations in AST and ALT levels, and earlier peak viremia with higher tissue viral loads, indicating impaired early viral control and accelerated systemic dissemination. Notably, one-year-old ferrets also developed measurable pathogenic manifestations, including febrile responses, progressive weight loss, detectable viremia, and multiorgan viral distribution, although disease progression was delayed and less severe compared with older animals. Within the same age group, differences in pathogenicity between genotypes B and F were limited. These findings demonstrate that host age is a major determinant of SFTSV disease severity and support the use of an age-stratified ferret model for preclinical evaluation of vaccines and antiviral therapeutics. ImportanceSFTS is an emerging tick-borne disease that can cause high fever, thrombocytopenia, and multi-organ failure, with particularly severe outcomes in older adults. Currently, no approved vaccines or specific antiviral treatments are available. Reliable animal models that recapitulate human disease are therefore essential for the development of effective countermeasures. Ferrets have recently been proposed as a useful model for SFTS, especially in aged animals, but the susceptibility of younger ferrets and the impact of viral strain differences remain unclear. Here we show that host age strongly determines disease severity in ferrets infected with two genetically distinct SFTS virus strains, establishing a flexible animal model for evaluating vaccines and antiviral therapies.

microbiology↗

Non-integrating direct reprogramming generates therapeutic endothelial cells with sustained vascular regeneration capacity enhanced by nanomatrix delivery

RationaleDirect reprogramming of fibroblasts into endothelial cells (rECs) using ETV2 shows promise for vascular regeneration. However, current approaches using integrating viral vectors pose clinical translation barriers, and poor long-term cell survival limits therapeutic efficacy. ObjectiveTo develop a clinically compatible method for generating rECs using non-integrating adenoviral ETV2 (Ad-ETV2) and enhance their engraftment and therapeutic efficacy through peptide amphiphile (PA) nanomatrix encapsulation. Methods and ResultsHuman dermal fibroblasts were reprogrammed using Ad-ETV2 and characterized by flow cytometry, RNA sequencing, and functional assays. Therapeutic efficacy was evaluated in murine hindlimb ischemia with or without PA-RGDS encapsulation over 12 months. Ad-ETV2 induced robust endothelial gene expression (CDH5, KDR, PECAM1) within 6 days, with 40-50% reprogramming efficiency. KDR+ Ad-rECs demonstrated functional endothelial properties including Ac-LDL uptake, tube formation, and exceptional proangiogenic factor secretion (200-fold higher HGF than HUVECs). RNA sequencing revealed rapid transcriptional reprogramming with fibroblast gene suppression and endothelial/angiogenic gene activation. In hindlimb ischemia, Ad-rECs significantly enhanced blood flow recovery and capillary density versus controls. Long-term analysis revealed sustained vascular contribution through three mechanisms: direct incorporation, perivascular support, and vessel guidance, persisting throughout 12 months--the longest reported follow-up for reprogrammed cells. PA-RGDS encapsulation markedly improved cell retention; while 75% of cells were lost by 3 months, retention stabilized thereafter with minimal additional loss through 12 months. ConclusionsAdenoviral ETV2 delivery enables efficient generation of clinically compatible rECs without genomic integration. These cells demonstrate potent and sustained therapeutic efficacy through multiple vascular regeneration mechanisms. PA-RGDS encapsulation significantly enhances long-term engraftment, establishing this combined approach as a promising platform for treating ischemic cardiovascular diseases.

cell biology↗

Polycomb group protein CBX7 represses cardiomyocyte proliferation via modulation of the TARDBP/Rbm38 axis

Cardiomyocyte (CM) proliferation notably decreases during the perinatal period. At present, regulatory mechanisms for this loss of proliferative capacity is poorly understood. CBX7, a polycomb group (PcG) protein, regulates the cell cycle but its role in CM proliferation is unknown. Here, we report that CBX7 inhibits proliferation of perinatal CMs by controlling TARDBP/Rbm38 pathway. Gene expression profiling demonstrated that CBX7 expression in the heart was low during the prenatal period, abruptly increased during the perinatal period, and sustained constantly throughout the adulthood. CBX7, when overexpressed via adenoviral transduction in neonatal CMs, reduced proliferation and promoted multinucleation of the CMs. Mutant mice carrying targeted inhibition of CBX7 in CMs exhibited cardiomegaly with increased proliferation of CMs at postnatal stages. Mechanistically, CBX7 interacted with TAR DNA-binding protein 43 (TARDBP) and positively regulated its downstream target, RNA Binding Motif Protein 38 (RBM38). Rbm38 was upregulated in the postnatal hearts and overexpression of RBM38 reduced proliferation of neonatal CMs. Together, this study provides a novel insight into the role of CBX7 in regulation of CM proliferation during the perinatal period.

developmental biology↗